Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
41.67
-2.55 (-5.77%)
At close: Feb 27, 2026, 4:00 PM EST
42.50
+0.83 (1.99%)
After-hours: Feb 27, 2026, 7:51 PM EST
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Collegium Pharmaceutical stock have an average target of 50.83, with a low estimate of 37 and a high estimate of 60. The average target predicts an increase of 21.98% from the current stock price of 41.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $56 → $54 | Strong Buy | Maintains | $56 → $54 | +29.59% | Feb 26, 2026 |
| Barclays | Barclays | Buy Maintains $58 → $56 | Buy | Maintains | $58 → $56 | +34.39% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 → $60 | Strong Buy | Reiterates | $46 → $60 | +43.99% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $48 → $56 | Strong Buy | Maintains | $48 → $56 | +34.39% | Jan 8, 2026 |
| Barclays | Barclays | Buy Initiates $58 | Buy | Initiates | $58 | +39.19% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
825.05M
from 780.57M
Increased by 5.70%
Revenue Next Year
734.82M
from 825.05M
Decreased by -10.94%
EPS This Year
8.10
from 1.73
Increased by 368.36%
EPS Next Year
6.33
from 8.10
Decreased by -21.82%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 868.4M | 870.5M | |||
| Avg | 825.1M | 734.8M | |||
| Low | 761.8M | 549.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 11.2% | 5.5% | |||
| Avg | 5.7% | -10.9% | |||
| Low | -2.4% | -33.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 10.59 | 8.41 | |||
| Avg | 8.10 | 6.33 | |||
| Low | 6.89 | 3.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 512.0% | 3.8% | |||
| Avg | 368.4% | -21.8% | |||
| Low | 298.2% | -53.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.